KIN-3248 is under clinical development by Kinnate Biopharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KIN-3248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KIN-3248 is under development for the treatment of FGFR2-fusion positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered urothelial carcinoma. The drug candidates acts by targeting FGFR2 and 3. It is administered through oral route.
Kinnate Biopharma overview
Kinnate Biopharma is a biotechnology company that focuses on the discovery and development of small molecule kinase inhibitor candidates for difficult-to-treat, cancers associated with genetic alterations. It is advancing the development of its lead-targeted therapy FGFR and RAF candidates. The company harnesses the proprietary, unique co-crystal structure of KIN002787 in the BRAF protein and biomarker-driven approach to drive the preclinical and clinical development of its translational research programs. Kinnate Biopharma also carries out small molecule development programs, such as Cyclin-Dependent Kinase 12 (CDK12) inhibitor. It has operations in San Francisco, the US. Kinnate Biopharma is headquartered in San Diego, California, the US.
For a complete picture of KIN-3248’s drug-specific PTSR and LoA scores, buy the report here.